Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DS 1594

Next Previous
Drug Profile

DS 1594

Alternative Names: DS-1594; DS-1594b

Latest Information Update: 06 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Menin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Precursor T-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 10 Dec 2022 Pharmacodynamics data from a preclinical trials in Acute myeloid leukaemia and Precursor T-cell lymphoblastic leukaemia-lymphoma presented at 64th American Society of Hematology Annual Meeting and Exposition (ASH-2022)
  • 07 Apr 2021 Daiichi Sankyo enters into research and development agreement with the University of Texas M. D. Anderson Cancer Center for DS 1594, prior to April 2021
  • 07 Apr 2021 Pharmacodynamics data from a preclinical trials in Acute myeloid leukaemia and Precursor T-cell lymphoblastic leukaemia-lymphoma released by Daiichi Sankyo

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top